Introduction
During the last two decades, a significant progress has been observed in breast reconstruction both with the introduction of skin-sparing mastectomy and with the use of immediate microvascular free tissue transfer. 1 After total mastectomy for breast cancer, several flap procedures allow for a reliable creation of a female breast using the abundant tissue of the lower abdomen. The transverse rectus abdominis muscle (TRAM) flap is one of the most frequently used method for autogenous breast reconstruction, being used either pedicled or as a free flap with microsurgical anastomosis. [1] [2] [3] Free tissue transfer from lower abdominal tissue to the thoracic wall requires a microsurgical anastomosis of the flap vessels (inferior epigastric artery and vein) to the recipient vessels, usually the internal mammary or the thoracodorsal artery and vein. Several early complications of the anastomosis, including iatrogenic damage, external compression, mechanical kinking, and venous or arterial thrombosis, may compromise blood supply to the flap with possible flap failure. In a large series of microvascular breast reconstruction, the incidence of anastomotic venous and arterial thrombosis was 1.5% and 0.6%, respectively. 4 Arterial anastomotic thrombosis was associated with a flap loss in 11.1% of the cases, while venous anastomotic thrombosis led to a flap loss in 26.7% of the cases. 4 These data suggest a need for medical prophylaxis of vascular thrombosis following microvascular free tissue transfer. However, postoperative anticoagulation and antiaggregation regimens are not standardized and it is unclear, which thromboembolic risk factors may contribute to anastomotic thrombosis.
A possible predisposing risk factor for anastomotic failure caused by thrombosis may be factor V (position 1691 G!A) Leiden (FVL) mutation with resistance to activated protein C, which is an established risk factor for macrovascular venous thromboembolism. 5 This point mutation on chromosome 1 was first described in 1994 and has hence been identified as a major risk factor for thromboembolic complications. [5] [6] [7] Heterozygous carriers of the gene mutation carry a 5-to 10-fold higher risk for deep vein thrombosis, and the risk is 80-fold higher in homozygous carriers. 5 In the Caucasian population, the prevalence of FVL mutation is between 2% and 10%, thus resembling the most common type of hereditary thrombophilia in the western world. 8 Among those patients with venous thromboembolism, FVL mutation can be detected in 20% of all cases. 5 The impact of FVL mutation on arterial thrombosis is unclear; some studies provide evidence for an increased risk while others were unable to link the mutation to arterial thrombotic disease. 5 We present a case of breast reconstruction using a free TRAM flap in a patient with known FVL mutation.
Case Report
A 37-year-old female patient with cancer (stage IIB, T3, N0, M0, G3) in the left breast had previously undergone mastectomy and axillary lymph node dissection in 2002. After 4 months, a local recurrence was detected, and the patient underwent a resection of the pectoralis major muscle followed by postoperative adjuvant radiotherapy (50 Gy). After 5 years, the patient presented disease-free at our clinic for late breast reconstruction using a free TRAM flap.
The medical history of the patient revealed a episode of a provoked deep vein thrombosis in 1991 following a long-distance flight to Mexico while the patient was taking hormonal anticonception (left popliteal vein). A second deep vein thrombosis occurred in 2001 (left femoral vein). Following the first thrombosis, a coagulation workup had been performed. The patient's mother and grandmother had both developed deep vein thrombosis during their life. The thrombophilia screening revealed a heterozygous FVL mutation and the patient was put on oral anticoagulation therapy with coumarin. At the time of her hospitalization for breast reconstruction, the patient had no previous abdominal surgery, did not smoke, and did not take oral contraceptive medication.
The preoperative physical exam showed a mild obesity (body mass index 26.5 kg/m 2 ). The coumarin therapy had been switched to subcutaneous lowmolecular-weight heparin (dalteparin) 2Â 5000 U/d. A preoperative laboratory investigation for coagulation parameters showed normal partial thrombin time (quick >100%), fibrinogen 2.5 g/L, antithrombin III (AT III) 75%, and lupus anticoagulans normal (<1.3). The patient's blood group was A, rhesus positive.
A free TRAM flap was performed with a total operative time of 450 minutes, intraoperative blood loss 500 mL, and blood transfusion 2 U. Intraoperative fluid substitution consisted of 3500 mL of Ringer's lactate solution and 200 mL of saline solution. The preoperative hemoglobin levels and hematocrit were normal (13.6 g/dL and 37.7%, respectively), postoperative hemoglobin levels were 10.3 g/dL and hematocrit 29.5%. Thrombocyte counts were normal preoperatively and postoperatively (308.000 and 241.000, respectively). The inferior epigastric vessels were anastomosed end-to-end with the internal mammarian vessels using a 9.0 prolene suture. While initially a good blood flow into the flap was observed, the flap became ischemic by the end of the operation. An immediate revision of both anastomoses was performed, revealing an arterial thrombosis at the microsurgical anastomosis and proximal to it in the internal mammary artery. A thrombectomy was performed using a Fogarthy catheter and the arterial anastomosis was repeated. Finally, a stable, good inflow into the flap was observed. Postoperatively, the patient received aspirin 100 mg/d and additionally unfractionated heparin (liquemin) 10.000 U intravenously (i.v.) per 24 hours were administered during the first 2 days. The patient received a total of 3 red blood cell units during the first 3 postoperative days to maintain a hemoglobin level of >10 g/dL. Appropriate hemoglobin levels and adequate tissue perfusion are essential to systemic oxygenation, flap survival, and wound healing.
On the third postoperative day, the flap again became vascularly compromised with the signs of venous congestion and slow recapillarization. An operative revision was performed and revealed thrombotic occlusion of both the venous and the arterial anastomosis. Again, not only the anastomosis was thrombosed but also the flow of the internal mammary artery was dramatically reduced, with the internal mammary artery thrombotically occluded proximally to the arterial anastomosis over a distance of 5 cm (Figure 1) . A thrombectomy was performed and the anastomoses were resutured using nylon 9.0.
Urokinase was administered into the arterial side of the flap at a dose of 100.000 U. By the end of the revision, a good flap flow was observed. Therapeutic anticoagulation was started 4 hours postoperatively with unfractionated heparin in increasing doses. Heparin therapy was monitored by daily measuring the thrombin times and partial thromboplastin time (pTT). On the sixth day after the first operation and despite adequate full-dose anticoagulation, the TRAM flap again appeared congested suggestive to thrombosis and another operative revision was performed. This time, no thrombosis was detected, but a small seroma was evacuated at the anastomosis side. On the fifteenth day following free TRAM procedure, the flap again appeared congested and a arteriography revealed a thrombus that required additional lysis (urokinase) through the femoral artery ( Figure 2 ). Flap flow was eventually good, but within 24 hours, the flaps again appeared ischemic and an angiography with lysis was repeated. A small leak in the anastomosis was observed, but a very long thrombus in the artery of the flap was also observed. The lysis was then stopped and the patient returned to the ward with the same anticoagulation regimen. A surgical revision showed no major bleeding. The flap perfusion remained critical. In the following hours, it had developed a skin necrosis at the lateral margin (30% circa of the surface) and a surrounding epidermolysis taking up to almost 50% of the flap surface (Figure 3) . On a late control 3 weeks following the initial operations, we found 50% flap loss due to fat and skin necrosis. Subsequently, a pedicled M. latissimus dorsi flap combined with a 355-cc breast prosthesis was used to allow final breast reconstruction (Figure 4 ).
Discussion
We have presented a case of a patient with known heterozygote FVL mutation in which repeated occlusion of microsurgical anastomosis of a TRAM flap occurred due to arterial and venous thrombosis. Despite a variety of pharmacological agents and interventional techniques available to salvage flaps, the key to successful salvage remains rapid recognition and early reexploration. Arterial and venous thrombosis of the microvascular anastomosis can be successfully treated by immediate thrombectomy and resuturing of the anastomosis.
Because the patient had undergone radiotherapy at the recipient site previously, one could argue that this may have caused an increased risk for thrombotic complications at the microvascular anastomosis. However, in a large series of TRAM flap complications encompassing 500 cases, previous radiation therapy was associated with increased seroma formation but not with thrombotic occlusion. 9 Aside from a minimal overweight, our patient had no other crucial factors contributing to an increased risk for thromboembolic complications other than the operation itself and hereditary thrombophilia. Although FVL mutation with resistance to activated protein C is a commonly accepted risk factor for deep venous thrombosis, its impact on thromboembolic complications following microsurgical anastomosis is unclear. Only 2 studies have previously investigated its role on microsurgical anastomosis outcome. 10, 11 Arnljots et al reported a series of 100 patients with free tissue transfers, in which 11 patients tested positive for pathologicalactivated protein C ratios and heterozygous FVL mutation. 10 The authors found no correlation between thrombophilic disorder and flap failure caused by thrombotic occlusion, and they suggest that rather nonconstitutional factors such as pedicle kinking and external compression may compromise blood flow into free flaps. An interpretation of this finding should consider that with an overall low incidence of vessel thrombosis between 0.6% and 1.8%, the number of patients may be too low to provide a statistical analysis with sufficient power. In contrast to the previous study, Ouriel et al found activated protein C resistance to be a risk factor for arterial occlusion at the anastomosis in patients undergoing infrainguinal bypass surgery. 11 Warnecke et al also described a case of a heterozygous FVL carrier with bilateral microvascular TRAM flap, in which the flap vessels revealed irreversible thrombosis intraoperatively and the flap was lost. 12 Retrospectively, we could have chosen a pedicled M. latissimus dorsi flap with a prosthesis as the first reconstructive choice, given the known risk of thrombobilia and microvascular anastomosis. However, the patient explicitly did not wish to have a breast prosthesis initially.
Taken together, further research on the impact of hereditary thrombophilia on vascular compromise following free tissue transfer seems necessary. Until stronger data on the impact of preexisting thrombophilia in patients undergoing free tissue transfer exist, preoperative thrombosis prophylaxis should be performed similar to that in high-risk patients.
